Advertisement

Pharmaceutical Chemistry Journal

, Volume 44, Issue 3, pp 147–150 | Cite as

Diffusion-transport properties of a polycomplex matrix system based on eudragit® EPO and Carbomer 940

  • R. I. Mustafin
  • T. V. Kabanova
  • E. R. Zhdanova
  • A. V. Bukhovets
  • V. R. Garipova
  • Sh. F. Nasibullin
  • V. A. Kemenova
Drug synthesis methods and manufacturing technology

New interpolyelectrolyte complexes (IPEC) between Eudragit® EPO (EPO) and Carbomer 940 (C940) were synthesized for assessment as controlled-release delivery carriers for oral systems. Depending on the structural properties, the resulting IPEC were distinct from the individual (co)polymers and their physical mixtures in terms of their swelling profiles in media simulating the gastrointestinal tract. Changes in structure and composition occurring within the polycomplex matrix on swelling were studied by IR spectroscopy, MT-DSC (modulated temperature differential scanning calorimetry), and elemental analysis. The mechanism underlying the transport of the model drug ibuprofen from the polycomplex matrix was identified.

Key words

Polycomplex controlled release ibuprofen Eudragit® Carbomer 940 

References

  1. 1.
    A. K. Bajpai, S. K. Shukla, S. Bhanu, S. Kankane, Progr. Polym. Sci., 33(11), 1088 – 1118 (2008).CrossRefGoogle Scholar
  2. 2.
    T. R. Hoare, D. S. Kohane, Polymer, 49, 1993 – 2007 (2008).CrossRefGoogle Scholar
  3. 3.
    C.-C. Lin, A. T. Metters, Adv. Drug Deliv. Rev., 58, 1379 – 1408 (2006).CrossRefPubMedGoogle Scholar
  4. 4.
    A. B. Zezi and V. B. Rogacheva, Advances in Polymer Chemistry and Physics [in Russian], Khimiya, Moscow (1973), pp. 3 – 30.Google Scholar
  5. 5.
    V. A. Kemenova, R. I. Mustafin, K. V. Alekseev, et al., Farmatsiya, 60(1), 67 – 71 (1991).Google Scholar
  6. 6.
    T. V. Kabanova, E. R. Zdanova, R. I. Moustafine, J. Control. Rel., 116(2), e33-e35 (2006).CrossRefGoogle Scholar
  7. 7.
    E. R. Zdanova, T. V. Kabanova, G. G. Chisameeva, R. I. Moustafine, Proc. 5th World Meeting on Pharm. Biopharm. & Pharm. Technol., Geneva (2006), Abstr. 19.Google Scholar
  8. 8.
    R. I. Mustafin and T. V. Kemenova, Khim.-Farm. Zh., 39(2), 34 – 38 (2005).Google Scholar
  9. 9.
    R. I. Moustafine, T. V. Kabanova, V. A. Kemenova, G. Van den Mooter, J. Control. Rel., 103, 191 – 198 (2005).CrossRefGoogle Scholar
  10. 10.
    A. Gómez-Carracedo, C. Alvarez-Lorenzo, J. L. Gómez-Amoza, A. Concheiro, Int. J. Pharm., 274, 233 – 243 (2004).CrossRefPubMedGoogle Scholar
  11. 11.
    R. I. Moustafine, I. M. Zaharov, V. A. Kemenova, Eur. J. Pharm. Biopharm., 63, 26 – 36 (2006).CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2010

Authors and Affiliations

  • R. I. Mustafin
    • 1
  • T. V. Kabanova
    • 1
  • E. R. Zhdanova
    • 1
  • A. V. Bukhovets
    • 1
  • V. R. Garipova
    • 1
  • Sh. F. Nasibullin
    • 1
  • V. A. Kemenova
    • 2
  1. 1.Medical UniversityKazan’Russia
  2. 2.Science Research Center of Biomedical TechnologyAll-Russian Science Research Institute of Medicinal and Aromatic PlantsMoscowRussia

Personalised recommendations